Genetic Variants of Annexin A2 and Cryptogenic Stroke

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT06880107

Acronym

GENANXVA

Enrollment

240

Registered

2025-03-17

Start date

2025-04-08

Completion date

2027-04-01

Last updated

2026-01-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Annexin A2, Fibrinolysis, Genetic Variants of Host, Stroke

Keywords

annexin A2, stroke, genetic variants, fibrinolysis

Brief summary

Stroke is the third most common cause of death in developed countries. Various mechanisms of ischemic stroke exist. However, in young population, in a third of cases, the cause of a stroke cannot be determined despite an extensive evaluation. Many studies have highlighted the link between stroke and fibrinolysis. Genetic variants of tPA and PAI-1 genes have been suggested to be the risk factors for stroke. ANXA2 plays a pivotal role in plasmin generation and fibrinolysis. Several studies showed the role of ANXA2 and S100A10 subunits in regulation of fibrinolysis in vivo. Recently, the efficacy of recombinant ANXA2 for fibrinolytic therapy in a rat embolic stroke has been demonstrated. Some single nucleotide polymorphisms in ANXA2 gene could be associated with increased risk of stroke in sickle cell disease. Therefore, these data invite us to test hypothesis that genetic variants of ANXA2 gene could be associated with ischemic stroke.

Interventions

BIOLOGICALblood withdrawal

blood withdrawal

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

SCREENING

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* Completed ischemic stroke defined as a rapidly developing focal neurologic deficit with no apparent cause other than a vascular origin that persisted beyond 24 hours in surviving patients * Age from 18 years old

Exclusion criteria

* Transient ischemic attack * Pregnancy

Design outcomes

Primary

Measure	Time frame
genetic variants of ANXA2	day 1
genetic variants of S100A10	day 1

Secondary

Measure	Time frame
blood ANXA2 concentration	day 1
blood S100A10 concentration	day 1
concentration of Autoantibodies directed against ANXA2	day 1
concentration of S100A10 directed against ANXA2	day 1

Countries

France

Contacts

CONTACTValéry SALLE, MD

salle.valery@chu-amiens.fr33+3 22 66 82 30

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026